In this work, we describe an accelerated solid-phase synthetic protocol for ordinary or difficult peptides involving air-bath heating and amide protection. For the Hmsb-based backbone amide protection, an optimized acyl shift condition using 1,4-dioxane was discovered. The efficiency and robustness of the protocol was validated in the course of preparation of classical difficult peptides and ubiquitin protein segments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c4ob02260b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimized digital workflow for pathologist-grade evaluation in bleomycin-induced pulmonary fibrosis mouse model.
Sci Rep
January 2025
Translational Research Division, Chugai Pharmaceutical Co., Ltd, 216 Totsuka-cho, Totsuka-ku, Yokohama-shi, Kanagawa, 244-8602, Japan.
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disorder of unknown etiology, characterized by interstitial fibrosis of the lungs. Bleomycin-induced pulmonary fibrosis mouse model (BLM model) is a widely used animal model to evaluate therapeutic targets for IPF. Histopathological analysis of lung fibrosis is an important method for evaluating BLM model.
View Article and Find Full Text PDFAn integrated approach for the accurate detection of HERV-K HML-2 transcription and protein synthesis.
Nucleic Acids Res
January 2025
Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY, NY 10029, USA.
Human endogenous retroviruses (HERVs) occupy a large portion of the human genome. Most HERVs are transcriptionally silent, but they can be reactivated during pathological states such as viral infection and certain cancers. The HERV-K HML-2 clade includes elements that recently integrated have in the human germ line and often contain intact open reading frames that possibly support peptide and protein expression.
View Article and Find Full Text PDFPancreas Irradiation for Treatment-Resistant Acute Cellular Rejection in a Severely Immunocompromised Pancreas after Kidney Transplant Recipient - Case Report.
Am J Transplant
January 2025
Division of Endocrinology, Diabetes, Metabolism & Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Treating acute rejection of a pancreas transplant in a severely immunocompromised patient with viral opportunistic infection is challenging due to the balance of rescuing from rejection without worsening the morbidity of infection and prolonging the infection episode. We present a case involving a pancreas-after-kidney transplant in a patient with CMV high-risk discordance (donor positive/recipient negative) and chronic lymphopenia who developed difficult-to-treat CMV disease approximately six months after pancreas transplant. Following the withdrawal of the antimetabolite due to the persistent CMV DNAemia and lymphopenia, the patient experienced acute pancreas rejection without adequate and sustained response to treatment with steroids and Thymoglobulin.
View Article and Find Full Text PDFTargeted antibody therapy as a treatment strategy for aggressive adult T-cell leukemia/lymphoma.
Leuk Res
January 2025
Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Sakuragaoka 8-35-1, Kagoshima, Japan. Electronic address:
The standard treatment for aggressive adult T-cell leukemia/lymphoma (ATL) is multi-agent chemotherapy, but the use of more intense cytotoxic anticancer agents is becoming more difficult with the aging of patients at the time of diagnosis. As a means of overcoming this hurdle, antibody drugs, which are supposed to be less toxic, have been developed for ATL. The advent of the anti-CC chemokine receptor 4 (CCR4) antibody mogamulizumab has significantly advanced ATL treatment.
View Article and Find Full Text PDFRobust peptide/RNA complexes prepared with microfluidic mixing for pulmonary delivery by nebulisation.
Drug Deliv Transl Res
January 2025
UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK.
Small interfering RNA (siRNA) and messenger RNA (mRNA) have drawn considerable attention in recent years due to their ability to modulate the expression of specific disease-related proteins. However, it is difficult to find safe, robust, and effective RNA delivery systems suitable for pulmonary delivery to treat lung diseases. In this study, two cationic peptides, namely LAH4-L1 and PEGKL4, were employed as non-viral vectors for siRNA and mRNA delivery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!